Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2016 - 2021)

Historic Other Accumulated Expenses for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to $20.0 million.

  • Neurocrine Biosciences' Other Accumulated Expenses rose 2903.23% to $20.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $20.0 million, marking a year-over-year increase of 2903.23%. This contributed to the annual value of $17.8 million for FY2020, which is 1710.53% up from last year.
  • Neurocrine Biosciences' Other Accumulated Expenses amounted to $20.0 million in Q3 2021, which was up 2903.23% from $22.0 million recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Other Accumulated Expenses peaked at $22.0 million during Q2 2021, and registered a low of $85000.0 during Q1 2018.
  • Over the past 5 years, Neurocrine Biosciences' median Other Accumulated Expenses value was $14.8 million (recorded in 2019), while the average stood at $11.5 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Other Accumulated Expenses plummeted by 8978.65% in 2018, and later surged by 428000.0% in 2019.
  • Over the past 5 years, Neurocrine Biosciences' Other Accumulated Expenses (Quarter) stood at $18.2 million in 2017, then tumbled by 89.79% to $1.9 million in 2018, then surged by 718.97% to $15.2 million in 2019, then rose by 17.11% to $17.8 million in 2020, then rose by 12.36% to $20.0 million in 2021.
  • Its Other Accumulated Expenses stands at $20.0 million for Q3 2021, versus $22.0 million for Q2 2021 and $18.1 million for Q1 2021.